Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

8.0K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
8.0K
Inhibitors of Gram-positive Cell Wall Synthesis01:23

Inhibitors of Gram-positive Cell Wall Synthesis

131
Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
131
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

11.7K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.7K
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

85
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
85
Biosynthesis of Polysaccharides01:26

Biosynthesis of Polysaccharides

981
Polysaccharides such as glycogen and starch are synthesized from nucleoside diphosphate sugars, primarily uridine diphosphate glucose (UDPG) and adenosine diphosphate glucose (ADPG). These activated glucose donors act as key intermediates in carbohydrate metabolism and biosynthesis. UDPG primarily involves glycogen synthesis in animals and many bacteria, while ADPG plays a fundamental role in starch synthesis in plants and certain bacteria.UDPG is formed when glucose-1-phosphate reacts with...
981

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Iterative Bump-and-Hole Engineering Creates a Bioorthogonal Reporter for <i>N</i>-Acetylglucosaminyltransferase I.

Journal of the American Chemical Society·2026
Same author

Antibacterial drug discovery: challenges and preclinical promises from synthetic small molecules.

Chemical Society reviews·2026
Same author

A changing HIV treatment landscape: what does lenacapavir mean for people living with HBV?

The lancet. Gastroenterology & hepatology·2026
Same author

A long-chain heparan sulfate capture mechanism directs paracrine GDNF-GFRα1 signalling through RET.

bioRxiv : the preprint server for biology·2026
Same author

Druggability is not static.

Nature chemical biology·2026
Same author

Coupling dead cell recognition to Fcγ receptors augments anticancer immunity.

Nature cancer·2026
Same journal

Efficient Syngas Photoproduction Enabled by Electronic Engineering of Co-Immobilized Imine COFs.

Angewandte Chemie (International ed. in English)·2026
Same journal

Pathway Controlled Phase Separation of Minimal Building Blocks Utilizing a Dissociative Chemical Transformation.

Angewandte Chemie (International ed. in English)·2026
Same journal

Interaction Hierarchy and Polymorphic Structure-Property Dynamics in Luminescent Molecular Crystals.

Angewandte Chemie (International ed. in English)·2026
Same journal

The Role of Zn-Hf Site Proximity and Oxygen Vacancies for Methanol Formation Over ZnHfO<sub>x</sub> Catalysts Under CO<sub>2</sub> Hydrogenation Conditions.

Angewandte Chemie (International ed. in English)·2026
Same journal

Breaking the Linear Scaling Relationship: Bioinspired Electronic Coupling in S-Bridged Fe-Fe Dual Sites for Efficient Oxygen Reduction.

Angewandte Chemie (International ed. in English)·2026
Same journal

Programming Bio-Bio Electronic Interfaces for Light-Driven Interspecies Electron Transfer.

Angewandte Chemie (International ed. in English)·2026
See all related articles

Related Experiment Video

Updated: Apr 21, 2026

A Converging Strategy for the Generation of a Virtually Sequenced cDNA Library from Unreferenced Pacific Oysters
12:14

A Converging Strategy for the Generation of a Virtually Sequenced cDNA Library from Unreferenced Pacific Oysters

Published on: June 13, 2019

6.0K

A Synergistic Inhibitor Development Strategy Against Human UDP-Galactose-4-Epimerase.

William M Browne1,2, Jonathan Pettinger3, Teresa Weckwerth1,2

  • 1Chemical Glycobiology Laboratory, Francis Crick Institute, London, UK.

Angewandte Chemie (International Ed. in English)
|April 20, 2026
PubMed
Summary
This summary is machine-generated.

Researchers developed novel small-molecule inhibitors for UDP-galactose-4-epimerase (GalE), a key enzyme in O-GalNAc glycosylation. This breakthrough offers new therapeutic strategies for cancer by targeting GalE, a promising oncology target.

Keywords:
covalentdrug discoveryfragment‐basedglycosylationmetabolism

More Related Videos

Demonstration of Heterologous Complexes formed by Golgi-Resident Type III Membrane Proteins using Split Luciferase Complementation Assay
05:28

Demonstration of Heterologous Complexes formed by Golgi-Resident Type III Membrane Proteins using Split Luciferase Complementation Assay

Published on: September 10, 2020

2.8K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

13.0K

Related Experiment Videos

Last Updated: Apr 21, 2026

A Converging Strategy for the Generation of a Virtually Sequenced cDNA Library from Unreferenced Pacific Oysters
12:14

A Converging Strategy for the Generation of a Virtually Sequenced cDNA Library from Unreferenced Pacific Oysters

Published on: June 13, 2019

6.0K
Demonstration of Heterologous Complexes formed by Golgi-Resident Type III Membrane Proteins using Split Luciferase Complementation Assay
05:28

Demonstration of Heterologous Complexes formed by Golgi-Resident Type III Membrane Proteins using Split Luciferase Complementation Assay

Published on: September 10, 2020

2.8K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

13.0K

Area of Science:

  • Biochemistry
  • Chemical Biology
  • Drug Discovery

Background:

  • O-GalNAc glycosylation is a crucial posttranslational modification in mammals.
  • Its dysregulation is linked to cancer metastasis and immune evasion, but mechanistic insights are limited by a lack of chemical tools.
  • UDP-galactose-4-epimerase (GalE) is essential for O-GalNAc biosynthesis, making it a potential therapeutic target.

Purpose of the Study:

  • To develop novel small-molecule inhibitors targeting the enzyme GalE.
  • To establish an efficient workflow combining covalent and non-covalent fragment screening with structure-based design.
  • To identify potent inhibitors for GalE, addressing the need for chemical tools in O-GalNAc glycosylation research.

Main Methods:

  • Integrated covalent and high-throughput crystallographic non-covalent fragment screening.
  • Structure-based drug design strategies.
  • Identification of a ligandable pocket near a reactive tyrosine residue in GalE.

Main Results:

  • Discovery of a potent sulfonyl fluoride covalent inhibitor targeting a non-cysteine residue.
  • Development of a covalent alkyne probe.
  • Identification of nanomolar non-covalent and covalent binders using structure-enabled fragment screening.

Conclusions:

  • Demonstrated a synergistic approach for GalE inhibition using next-generation chemical matter.
  • Highlighted the potential for targeting non-cysteine residues in chemical biology.
  • Provided valuable tools for studying O-GalNAc glycosylation and developing new oncology therapeutics.